Abstract
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1,2,3,4,5,6,7,8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
【초록키워드】 COVID-19, coronavirus disease, neutralizing antibody, SARS-CoV-2, Efficacy, Vaccine, coronavirus, pandemic, clinical trials, immunization, immune, Adenovirus, Protein, Ad26.COV2.S, non-human primates, vector, nasal swab, intranasal, Neutralizing antibody response, single dose, Protective, rhesus macaque, Bronchoalveolar lavage, Safe, acute respiratory syndrome, serotype, Ad26, Complete, effective, immunized, robust, evaluated, required, provided, correlated, expressing, S variant, single-shot vaccine, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2, Vaccine, rhesus macaque, Ad26, PROTECT, Single-shot,